Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686219 | 0.86 | LMNA (0.35) | — | |
| SCHEMBL5680158 | 0.86 | TSHR (0.30) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL28799517 | 0.84 | TSHR (0.34) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL1569081 | 0.81 | PARP1 (0.33) | — | |
| SCHEMBL12562662 | 0.79 | PLK1 (0.33) | — | |
| SCHEMBL3043749 | 0.78 | TSHR (0.37) | TSHR | |
| SCHEMBL5581539 | 0.78 | MAPK1 (0.33) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL132243 | 0.76 | TSHR (0.32) | TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL29082823 | 0.75 | — | — | |
| Bromide SCHEMBL22206792 | 0.74 | TSHR (0.32) | TSHRMAPK1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | ENZACTA R & D LIMITED | 2007-07-19 | — | — | US | disclosed |
| US-7138122-B2 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-0988059-B8 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | PROTHERICS MOLECULAR DESIGN LT (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-0988059-B1 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| US-6867231-B1 | Therapeutic systems | ENZACTA R & D LIMITED (GB) | 2005-03-15 | — | — | US | disclosed |
| EP-1468698-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20030086933-A1 | Therapeutic systems | ENZACTA R & D LIMITED | 2003-05-08 | — | — | US | disclosed |
| EP-0988059-A2 | HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT | ENZACTA R & D LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057662-A2 | THERAPEUTIC SYSTEMS | ENZACTA R & D LIMITED (GB) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070166296-A1 | Therapeutic Systems | NQO2, NQO1, NAPRT | TSHR 2265/4885MAPK1 4291/4885HSD17B10 778/4885 |
| US-20030086933-A1 | Therapeutic systems | NQO2, NQO1, NAPRT | TSHR 2265/4885MAPK1 4291/4885HSD17B10 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.